NON-CYCLING haemopoietic stem cells appear to be resistant to the toxic effects of bleomycin (BLM) (Twentyman & Bleehen, 1973; Briganti et al., 1975 ) the well known anticancer antibiotic which in experimental research (Matsuda et al., 1968; Boggs et al., 1974) and in clinical practice (Ichikawa et al., 1970; Mosher et al., 1972; Umezawa, 1976) avoids major marrow toxicity. Proliferating stem cells are however more sensitive to the toxic action of the drug (Twentyman & Bleehen, 1973; Briganti et al., 1975) . It is therefore possible that if tile drug is given in fractionated doses, the quantitative and proliferative changes in the stem-cell population caused bv the first doses, although slight, might modify the susceptibility of the population to the follow-ing doses of the drug. In fact relatively large doses of BLM, given once daily for 3 days to normal mice, caused a small but persistent reduction of the marrow's ability to produce spleen colonies (Boggs et al., 1974) . The present study has been undertaken to investigate the effects on mouse marrow stem cells of prolonged (over many weeks) administration of BLM in much smaller daily doses, extrapolated from those used in clinical practice by an appropriate conversion factor (Freireich et al., 1966 anticancer drugs (Pannacciulli et al., 1977a, b Bleehen, 1973) . This may explain why the same amount of proliferation-dependent BLM given in repeated doses would result in a depletion similar to the above, considering that at each dose the kinetics of the haemopoietic population have been altered by the previous doses.
The severe depletion of marrowT CFU-S induced by repeated small doses of BLM may be the result of a direct action of the cytotoxic druig on the stem cells (destruction, hampered differentiation, prolonged generation time) plus the indirect consequence of the compensatory effort of haemopoiesis (enhanced removal of pluripotent stem cells due to differentiation to committed precursor cells and migration to other haemopoietic sites).
The recovery of (CFU-S takes place in spite of the continued administration of the drug. Even in clinical observations of marrow suppression there was recovery to pretreatment, counts, in spite of continued BLM administration (Krakoff & Yagoda, 1973) . It is possible that in the long run the inactivation of the drug, already particularly effective in marrow (Umezawa, 1976) becomes progressively more efficient. Alternatively the adaptation of the haemopoietic system may further evolve to reach a new steady state based on a different dynamic equilibrium.
The pattern seen during chronic administration of BLM seems comparable with that found in rats under continuous irradiation (45-50 rad/day) when a tnormal red-cell production is associated with a severely depleted stem-cell population (Lamerton, 1966; Blackett, 1967 
